Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371627 | 0.86 | HPGDS (0.59) | PDGFRBPDGFRAALDH1A1EGFRNCF1 | |
| SCHEMBL17585451 | 0.86 | PDGFRB (0.54) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL7028923 | 0.85 | ALDH1A1 (0.70) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL15648249 | 0.83 | PDE3B (0.47) | PDGFRBPDGFRAALDH1A1HPGDNPC1 | |
| SCHEMBL434861 | 0.80 | PDGFRB (0.59) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL9156972 | 0.79 | ALDH1A1 (0.62) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL621672 | 0.79 | PDGFRB (0.58) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL27918947 | 0.79 | PDGFRB (0.58) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL1928147 | 0.79 | PDGFRB (0.58) | PDGFRBPDGFRAALDH1A1F2GLA | |
| SCHEMBL27930034 | 0.79 | PDGFRB (0.58) | PDGFRBPDGFRAALDH1A1F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695964-A1 | Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines | NOVEXEL (FR) | 2006-08-30 | — | — | EP | claimed |
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | claimed |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200131158-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2020-04-30 | — | — | US | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-1370550-A1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-12-17 | — | — | EP | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| EP-1337529-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-08-27 | — | — | EP | disclosed |
| US-6603005-B2 | Bactericides | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
| WO-2002072572-A1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2002-09-19 | — | — | WO | disclosed |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | NOVEXEL (FR) | 2002-08-15 | — | — | US | disclosed |
| WO-2002040474-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | PDGFRB 3444/4885PDGFRA 2639/4885ALDH1A1 838/4885 |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | PDGFRB 4560/4885PDGFRA 4124/4885ALDH1A1 1808/4885 |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | TOP2A, TOP1, TOP2B | PDGFRB 3565/4885PDGFRA 3830/4885ALDH1A1 3195/4885 |
| US-20200131158-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | TOP2A, TOP1, TOP2B | PDGFRB 3565/4885PDGFRA 3830/4885ALDH1A1 3195/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | PDGFRB 4560/4885PDGFRA 4124/4885ALDH1A1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.